GODAVARIB

Godavari Biorefineries Limited

NSE
Last Traded Price
₹264.05 -2.15 (-0.81%)
Open
₹266.9
High
₹271
Low
₹259
Prev Close
₹266.2
Industry
Diversified FMCG
Market Cap
1351.30 Cr

Price Chart

Loading chart data...
Data delayed by up to 5 minutes. Not live.

Filing History

Recent corporate announcements and filings for GODAVARIB

Governance Neutral
2026-06-30 15:53
- Re-appointment of Mr. Nitin Mehta as an Independent Director for a term of 5 years, effective July 1, 2026. - Re-appointment of Dr. Sangeeta Srivastava as a Whole Time Director (Executive Director) for a term of 3 years, effective August 1, 2026.
Governance Positive
2026-06-29 18:50
- Results of the Postal Ballot for resolutions dated May 22, 2026, were declared on June 29, 2026. - Re-appointment of Mr. Nitin Mehta as an Independent Director was approved with 99.9928% votes in favour. - Re-appointment of Dr. Sangeeta Srivastava as a Whole Time Director was approved with 99.9931% votes in favour. - Both resolutions passed with the requisite majority.
Business Update Positive
2026-06-29 16:24
- Godavari Biorefineries Ltd commenced operations of its corn/grain-based distillery at Sameerwadi Unit on June 29, 2026. - The new capacity addition is 200 KLPD, with an approximate investment of ₹130 Cr, financed through internal accruals and debt. - This provides dual-feedstock capability for resilient ethanol production, supporting India's ethanol blending program.
Routine Neutral
2026-06-26 15:23
- Intimation of the closure of the trading window for dealing in the company's securities. - The trading window will be closed from July 1, 2026, until 48 hours after the declaration of financial results for the quarter ending June 30, 2026. - This is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.
Business Update Positive
2026-06-16 10:09
- Godavari Biorefineries Ltd received a patent grant from the Japanese Patent Office for "5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER". - The patent covers compounds with strong inhibitory effects on cancer and cancer stem cells, showing efficacy against breast and prostate cancer. - Patent Number: 7869786. Registered on: May 26, 2026.